RSV Vaccine for Pregnant Women and Infants
PMG Research of McFarland Clinic
Respiratory Syncytial Virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in infants, especially in those with risk factors including prematurity. RSV infections in pregnant women may cause extended hospital stays and, in some cases, pre-term labor. Currently, there is no specific RSV treatment or vaccine to protect against RSV infection.
A research study is evaluating an investigational RSV vaccine given to women during pregnancy. The antibodies produced by the mother after vaccination should cross over to her baby to help fight against RSV-related infections after birth.
This research study may be an option if you:
• Are between 24 – 36 weeks pregnant
• Have received an ultrasound at 18 weeks gestation
Other criteria apply.
Qualified participants will receive all study-related care and study vaccine at no cost.
Patient Commitment Duration
Up to 10 months for mother Up to 24 months for child
Financial compensation may be provided for time and travel expenses.
Number of visits in study
Up to 3 study visits for mother Up to 5 study visits for child